Determination of 6-thioguanosine diphosphate and triphosphate and nucleoside diphosphate kinase activity in erythrocytes: Novel targets for thiopurine therapy?

Therapeutic Drug Monitoring

Volumn 32, Issue 2, 2010, Pages 119-128

  Karner, Susanne ^a   Shi, Shaojun ^a,b   Fischer, Christine ^a   Schaeffeler, Elke ^a   Neurath, Markus F ^c   Herrlinger, Klaus R ^d   Hofmann, Ute ^a   Schwab, Matthias ^a,e  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d ROBERT BOSCH HOSPITAL   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

6 thioguanosine 5 phosphate; Azathioprine; Nucleoside diphosphate kinase; Thioguanine nucleotide; Thiopurines

Indexed keywords

6 THIOGUANOSINE DIPHOSPHATE; AZATHIOPRINE; DRUG METABOLITE; HEMOGLOBIN; NUCLEOSIDE DIPHOSPHATE KINASE; NUCLEOSIDE DIPHOSPHATE KINASE A; NUCLEOSIDE DIPHOSPHATE KINASE B; THIOGUANOSINE; THIOGUANOSINE PHOSPHATE; THIOGUANOSINE TRIPHOSPHATE; UNCLASSIFIED DRUG; 6-THIOGUANOSINE 5'-DIPHOSPHATE; 6-THIOGUANOSINE 5'-TRIPHOSPHATE; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; NUCLEOTIDE; PURINE DERIVATIVE;

ADULT; AGED; ARTICLE; BIOTRANSFORMATION; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DEGRADATION; DRUG MECHANISM; DRUG TARGETING; ENTERITIS; ENZYME MECHANISM; ERYTHROCYTE; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; ION PAIR CHROMATOGRAPHY; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; REPRODUCIBILITY; ULCERATIVE COLITIS; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; CATALYSIS; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; MIDDLE AGED; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AZATHIOPRINE; CATALYSIS; DRUG DELIVERY SYSTEMS; ENZYME ACTIVATION; ERYTHROCYTES; FEMALE; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; HUMANS; MALE; MIDDLE AGED; NUCLEOSIDE-DIPHOSPHATE KINASE; PURINES; THIONUCLEOTIDES; YOUNG ADULT;

EID: 77950262836     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181d12f19     Document Type: Article

References (29)

1. Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet. 2007;46: 187-208.
2. Tidd DM, Paterson AR. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res. 1974;34:738-746.
3. Somerville L, Krynetski EY, Krynetskaia NF, et al. Structure and dynamics of thioguanine-modified duplex DNA. J Biol Chem. 2003;278: 1005-1011.
4. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111:1133-1145.
5. Poppe D, Tiede I, Fritz G, et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol. 2006;176: 640-651.
6. Lennard L, Lilleyman JS, Van Loon J, et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet. 1990;336:225-229.
7. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999;91:2001-2008.
8. Bergan S, Rugstad HE, Bentdal O, et al. Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation. Transplantation. 1998;66:334-339.
9. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology. 2000;118:705-713.
10. Osterman MT, Kundu R, Lichtenstein GR, et al. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology. 2006;130:1047-1053.
11. Neurath MF, Kiesslich R, Teichgräber U, et al. 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease. Clin Gastroenterol Hepatol. 2005;3:1007-1014.
12. Mourad N, Parks RE Jr. Erythrocytic nucleoside diphosphokinase. II. Isolation and kinetics. J Biol Chem. 1966;241:271-278.
13. Parks RE Jr, Brown PR. Incorporation of nucleosides into the nucleotide pools of human erythrocytes. Adenosine and its analogs. Biochemistry. 1973;12:3294-3302.
14. Gilles AM, Presecan E, Vonica A, et al. Nucleoside diphosphate kinase from human erythrocytes. Structural characterization of the two poly-peptide chains responsible for heterogeneity of the hexameric enzyme. J Biol Chem. 1991;266:8784-8789.
15. Bosnar MH, Bago R, Cetković H. Subcellular localization of nm23/ NDPK A and B isoforms: a reflection of their biological function? Mol Cell Biochem. 2009;329:63-71.
16. Herrlinger KR, Fellermann K, Fischer C, et al. Thioguanine-nucleotides do not predict efficacy of thioguanine in Crohn's disease. Aliment Pharmacol Ther. 2004;19:1269-1276.
17. Finkel JM. Fluorometric assay of thioguanine. J Pharm Sci. 1975;64: 121-122.
18. Rabel SR, Stobaugh JF, Trueworthy R. Determination of intracellular levels of 6-mercaptopurine metabolites in erythrocytes utilizing capillary electrophoresis with laser-induced fluorescence detection. Anal Biochem. 1995;224:315-322.
19. Pulido-Cejudo G, Gagnon J, Leclerc JM, et al. Measurement of nucleoside diphosphate kinase-Nm23 activity by anion-exchange high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1994;660:37-47.
20. Lambeth DO, Muhonen WW. The direct assay of kinases and acyl-CoA synthetases by HPLC: application to nucleoside diphosphate kinase and succinyl-CoA synthetase. Anal Biochem. 1993;209:192-198.
21. de Graaf P, de Boer NK, Jharap B, et al. Stability of thiopurine metabolites: a potential analytical bias. Clin Chem. 2008;54:216-218.
22. Lavi LE, Holcenberg JS. A rapid and sensitive high-performance liquid chromatographic assay for 6-mercaptopurine metabolites in red blood cells. Anal Biochem. 1985;144:514-521.
23. Kong CM, Parks RE Jr. Incorporation of the purine moieties of guanosine and inosine analogs into nucleotide pools of human erythrocytes. Biochem Pharmacol. 1975;24:807-813.
24. Dean BM, Perrett D, Sensi M. Changes in nucleotide concentrations in the erythrocytes of man, rabbit and rat during short-term storage. Biochem Biophys Res Commun. 1978;80:147-154.
25. Vikingsson S, Carlsson B, Almer SH et al. Monitoring of thiopurine metabolites in patients with inflammatory bowel disease\what is actually measured? Ther Drug Monit. 2009;31:345-350.
26. Bianchi PA, Farina MV, Polli E. Phosphorylation of thymidine diphosphate in resting and proliferating mammalian cells. Biochim Biophys Acta. 1964;91:323-325.
27. Bokemeyer B, Teml A, Roggel C, et al. Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther. 2007;26:217-225.
28. Seidman EG. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord. 2003;3(Suppl 1):S30-S38.
29. Schaeffeler E, Zanger UM, Eichelbaum M, et al. Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups. Clin Chem. 2008;54:1637-1647.